Intralesional steroid injection for management of acute idiopathic dacryoadenitis: a preliminary result.
OBJECTIVE
To evaluate the efficacy of intralesional injection of steroid as a new line of therapy in treatment of the acute form of an isolated idiopathic dacryoadenitis.


METHODS
Five patients with unilateral isolated acute idiopathic dacryoadenitis were included in the study. In 2 patients, the pathology was recurrent. Intralesional injection of 2 to 4 ml betamethasone suspension (1 ml contains 2 mg betamethasone sodium phosphate and 5 mg betamethasone dipropionate) was followed by cold compression for 6 hours. Systemic nonsteroidal anti-inflammatory drugs were given for 2 weeks after the injection.


RESULTS
Dramatic response was achieved within 7 days after injection in all cases. No patient had recurrence during the follow-up period of 8 to 19 months.


CONCLUSIONS
The excellent preliminary results make this new line of therapy highly promising. However, more study and long-term follow-up are recommended.
Mohammad
Abd El-Nasser A
Ael-N
Department of Ophthalmology, Assiut University, Assiut, Egypt. rehab@acc.aun.edu.eg
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001623:Betamethasone / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D002648:Child; D003607:Dacryocystitis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D012008:Recurrence; D014057:Tomography, X-Ray Computed
D005938:Glucocorticoids; D009883:Ophthalmic Solutions; C028994:betamethasone sodium phosphate; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone